Amphastar Pharmaceuticals (AMPH) Work In Process (2015 - 2026)

Amphastar Pharmaceuticals has reported Work In Process for 12 years, with the latest figure at $44.3 million in Q2 2026.

• On a quarterly basis, Work In Process rose 1.64% year-over-year to $44.3 million in Q2 2026; TTM through Jun 2026 was $44.3 million, a 1.64% increase from a year earlier, with the FY2025 full-year figure at $40.4 million, up 23.27% from the prior year.
• Work In Process was $44.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $42.6 million in the prior quarter.
• The five-year high for Work In Process was $44.3 million in Q2 2026, with the low at $28.3 million in Q3 2023.
• Average Work In Process over 5 years is $37.5 million, with a median of $38.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Work In Process declined 26.63% in 2023, then surged 31.34% in 2025.
• Over 5 years, Work In Process stood at $37.1 million in 2022, then fell by 16.9% to $30.8 million in 2023, then grew by 6.44% to $32.8 million in 2024, then gained by 23.27% to $40.4 million in 2025, then climbed by 9.54% to $44.3 million in 2026.
• The last three Work In Process figures came in at $44.3 million (Q2 2026), $42.6 million (Q1 2026), and $40.4 million (Q4 2025), per Business Quant data.